Latest data on lecanemab to be presented at Alzheimer's Asso

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid...

Related Keywords

Sweden , California , United States , San Diego , Stockholm , Uppsala , Uppsala Lan , Swedish , Oskar Bosson , Gunilla Osswald , Uppsala University , Vp Communications , Alzheimer Association International Conference , National Institutes Of Health , National Institute On , Drug Administration , Alzheimer Clinical Trial Consortium , Nasdaq Stockholm , Association International Conference , Biologics License Application , Prescription Drug User Fee Act , Pacific Time , Presentation Number , Developing Topics , Infusion Reactions , Randomized Phase , Open Label Extension , Diverse Participant Recruitment , Disease Prevention Trial , Autopsy Findings , Received Long Term Treatment , Dose Selection , Early Alzheimer , Fixed Subcutaneous Dose , Interaction Characteristics Between Amyloid , Clinical Benefits , Elenbecestat Early Alzheimer , Clinical Trial Consortium , National Institute , National Institutes , Breakthrough Therapy , Commercialization Agreement , Nasdaq Stockholm Mid Cap , Bioarctic ,